Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
61 participants
INTERVENTIONAL
2012-08-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Performance Comparison Between Comfilcon A and Senofilcon C Lenses
NCT02920957
Clinical Comfort Evaluation of Two Marketed Spherical Contact Lenses
NCT02356692
Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses
NCT01629693
Clinical Validation Study of Comfilcon A Multifocal Toric Contact Lenses
NCT03417557
A Bilateral Dispensing Comparison of Comfilcon A Over Senofilcon C Contact Lenses
NCT03684928
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Senofilcon A
Senofilcon A; Comfilcon A
Senofilcon A; Comfilcon A
Senofilcon A; Comfilcon A
Comfilcon A; Senofilcon A
Comfilcon A; Senofilcon A
Comfilcon A
Comfilcon A; Senofilcon A
Senofilcon A; Comfilcon A
Senofilcon A; Comfilcon A
Comfilcon A; Senofilcon A
Comfilcon A; Senofilcon A
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Senofilcon A; Comfilcon A
Senofilcon A; Comfilcon A
Comfilcon A; Senofilcon A
Comfilcon A; Senofilcon A
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has had an oculo-visual examination in the last two years
* Is at least 18 years of age and has full legal capacity to volunteer
* Has read and understood the information consent letter
* Is willing and able to follow instructions and maintain the appointment schedule
* Is correctable to a visual acuity of 20/30 or better (in each eye) with their habitual vision correction
* Currently wears soft contact lenses at least 3 days a week, 8 hours a day
* Has clear corneas and no active ocular disease
* Has not worn lenses for at least 12 hours before the examination
* Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
* No amblyopia
* No evidence of lid abnormality or infection (e.g. entropion, ectropion, chalazia, recurrent styes)
* No clinically significant slit lamp findings (e.g. infiltrates or other slit lamp findings Grade 2 or above: corneal edema, tarsal abnormalities, and conjunctival injection).
* No other active ocular disease (e.g. glaucoma, history of recurrent corneal erosions, cornea \[infiltrates\], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology)
* No aphakia
* Has prescription to match the available power range.
Exclusion Criteria
* Greater than 0.75 of refractive astigmatism in either eye
* Has never worn contact lenses before
* Wears contact lenses on an extended wear basis
* Has any systemic disease affecting ocular health
* Is a known sufferer of ocular allergies
* Is taking medication, such as oral antihistamines, antihistamine eye drops, oral and ophthalmic beta-adrenergic blockers (e.g. Propanolol, Timolol), anticholinergics, oral steroids and any prescribed or over-the-counter eye medication, except artificial tears or eye lubricants
* Has any clinically significant lid or conjunctival abnormalities, neovascularization, corneal scars or corneal opacities
* Is aphakic
* Has undergone corneal refractive surgery.
* Is wearing monovision
* Is participating in any other type of clinical or research study
* Female who is currently pregnant or is breast-feeding
* Has \> grade 1 ocular corneal staining in both type and extent by \> grade 2 in either type or extent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CooperVision, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jan Bergmanson, OD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Houston College of Optometry, TERTC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Houston College of Optometry, TERTC
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV-12-54
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.